Neurocrine Biosciences (NBIX) Current Deferred Revenue (2010 - 2018)

Neurocrine Biosciences has reported Current Deferred Revenue for 9 years, with the latest figure at $731000.0 in Q1 2018.

• For the quarter ending Q1 2018, Current Deferred Revenue fell 79.42% year-over-year to $731000.0; the trailing twelve-month figure through Mar 2018 stood at $731000.0 (down 79.42% YoY), and the FY2017 full-year result was $731000.0, down 79.27% from the prior year.
• Current Deferred Revenue for Q1 2018 stood at $731000.0, roughly flat from $731000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $10.2 million in Q1 2015, with the low at $52000.0 in Q2 2014.
• Historically, Current Deferred Revenue has averaged $2.8 million across 5 years, with a median of $2.0 million in 2014.
• Annual changes were most pronounced in 2015 — Current Deferred Revenue soared 8471.43% — and 2016, when it tumbled 96.62%.
• Neurocrine Biosciences' Current Deferred Revenue stood at $119000.0 in 2014, then soared by 8471.43% to $10.2 million in 2015, then sank by 65.43% to $3.5 million in 2016, then plunged by 79.27% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
• The last three Current Deferred Revenue figures came in at $731000.0 (Q1 2018), $731000.0 (Q4 2017), and $731000.0 (Q3 2017), per Business Quant data.